NEW HAVEN, Conn., Sept. 11, 2025 /PRNewswire/ — XingImaging in partnership with SynuSight Biotech has received funding of $3.84M from The Michael J. Fox Foundation to conduct studies on ¹⁸F-FD4, a specific α-synuclein (α-syn)-targeted PET tracer. Based on prior investigator-initiated trials, the SynuSight Biotech developed technology, showed the potential to become the world’s first α-syn-targeted PET tracer for Parkinson’s disease (PD), multiple system atrophy (MSA), and rapid eye movement sleep behavior disorder (RBD).

XingImaging is a leading neuroimaging and radiopharmaceutical services company serving as SynuSight’s preclinical and clinical CRO partner. Under the grant framework, XingImaging will provide critical support for regulatory filings and clinical trial execution while delivering key scientific expertise to help drive the project toward clinical translation.

Parkinson’s disease, the second most common neurodegenerative disease after Alzheimer’s disease, is estimated to affect over 10 million people worldwide. Characterized by the progressive loss of dopamine neurons and the accumulation of pathological α-syn aggregates in the brain, PD leads to debilitating motor symptoms (e.g., tremors, rigidity) and non-motor complications (e.g., cognitive decline, loss of sense of smell).

Current diagnosis relies heavily on clinical symptom assessment, which often delays detection until significant neuronal damage has occurred. Early-stage symptoms, such as subtle movement changes or sleep disturbances, frequently overlap with other conditions, complicating accurate diagnosis. Current clinical imaging tools of PD (e.g., DATScan) provide valuable insights into dopaminergic dysfunction or metabolic changes—but crucially, they lack molecular specificity for biomarkers. This limitation has hindered timely intervention and the development of disease modifying therapies aimed at halting or reversing disease progression.

SynuSight R&D team leveraged structural biology approaches to systematically determine the molecular architectures of α-Syn fibrils and probe the binding specificity between candidate molecules and this pathological biomarker. These insights enabled the rational design of FD4, a novel PET tracer engineered for selective α-Syn fibrils targeting. Preclinical and early clinical data demonstrate, a robust and selective binding to α-syn fibrils and allows identification of α-syn pathology in the early stage of synucleinopathies, enabling proactive therapeutic strategies.

Roger Gunn, CSO at Xing Imaging, and PI says, “This represents a pivotal opportunity to advance one of the most promising alpha-synuclein PET tracers in humans, ensuring its full characterization and optimization for imaging in Parkinson’s disease. We are deeply grateful for the support of the Michael J. Fox Foundation and share their commitment to developing a robust PET imaging biomarker targeting the core pathological hallmark of PD. Such a biomarker would significantly enhance our understanding of the disease, its progression, and will play a central role in clinical trials evaluating new treatments.”

Roger Fan, CEO at SynuSight Biotech, says ‘We are deeply honored to receive support from the Michael J. Fox Foundation for the development of the ¹⁸F-FD4 program. Our early Investigator-Initiated Trials have already demonstrated superior imaging performance in patients with PD, MSA, and RBD. Backed by the MJFF grant, we are now well-positioned to accelerate our validation efforts through additional clinical studies with XingImaging and fully unleash the potential of ¹⁸F-FD4 to advance the development of disease-modifying therapies. Ultimately, we believe this tracer has the potential to transform the diagnosis and management of diseases and benefit millions of patients worldwide.’

“We continue to monitor the tremendous progress and advances in alpha-synuclein imaging,” says Jamie Eberling, PhD, senior vice president of research resources at The Michael J. Fox Foundation. “XingImaging and SynuSight Biotech’s F-FD4 programming is another hopeful step toward an urgently needed tool that could clearly measure, quantify and visualize brain pathology in Parkinson’s disease.”

About SynuSight:
SynuSight Biotech is committed to pioneering transformative diagnostic and therapeutic solutions for neurodegenerative diseases through cutting-edge scientific expertise and innovative technology platforms, ultimately benefiting millions of patients worldwide.

SynuSight team specializes in studying the misfolding and pathological aggregation of proteins such as α-Syn, tau, and Aβ. By integrating cutting-edge technologies like Cryo-EM electron diffraction, Helical filament imaging, and In-cell NMR spectroscopy, SynuSight has built unparalleled expertise in key neurodegenerative disease targets, unlocking new possibilities for innovative therapeutic molecule development.

About XingImaging:
XingImaging is based in New Haven, CT with over 24,000 sq ft. of research space and over 50 staff members. Our team is organized into Clinical, Chemistry, and Imaging Sciences divisions with administrative and project support including Regulatory Affairs, Quality Assurance, Imaging and Data Management Services, Information Technology, and Business Operations.

STUART, Fla., Sept. 11, 2025 /PRNewswire/ — Health In Tech (Nasdaq: HIT) will host its 2025 Annual Stockholder Meeting on Friday, October 3, 2025, at 10:00 AM ET live via virtual webcast.

To participate in the Annual Stockholders Meeting, stockholders should visit www.cleartrustonline.com/HIT or the Company’s Investor Relations site at https://healthintech.investorroom.com/  under “News & Events,” and enter the 12-digit control number found in the proxy materials. Guests may also access the Annual Shareholders Meeting in listen-only mode. No control number is required for guests.

During the meeting, stockholders as of the 2025 Annual Meeting record date (close of business on August 6, 2025) will be able to vote their shares electronically and will be able to submit questions during the meeting.

A live webcast and replay will be accessible on the Company’s website at https://healthintech.investorroom.com/Events.

About Health In Tech

Health In Tech (Nasdaq: “HIT”) is an Insurtech platform company backed by third-party AI technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs. Learn more at healthintech.com.

Investor Contact

Investor Relations:
ir@healthintech.com

MUNICH, Sept. 11, 2025 /PRNewswire/ — On September 9, SERES Power celebrated the global launch of its latest-generation SERES Super Range-Extender System, high-efficiency engine technology, and new-generation distributed e-Drive system during IAA MOBILITY 2025. More than 60 representatives from AVL, Bosch, Mahle, Schaeffler, Valeo, Stellantis, Mubea, Infineon and other companies, and international media attended this technology launch and salon event. Taking this opportunity, SERES Power will continue to carry out collaborative innovation with supply chain partners, jointly provide safer, more intelligent, and more convenient intelligent mobility solutions for global users.

The new generation of SERES Super Range-Extender System is based on “Saiyi (C2E) Range-Extender Architecture” and “RoboREX Intelligent Control Technology”, featuring three leading advantages: quiet, highly integrated, and highly efficient. The C2E Architecture adopts All-in-ONE integrated design concept, with deep integration of engine and motor, control systems, and housing to enable ultimate compactness and cost control. RoboREX revolutionizes the range-extender’s operating mode from passive to active control, enabling intelligent active energy management.

In terms of efficiency performance, the comprehensive fuel consumption is reduced by 15%, noise perception is reduced by 90%, the actual efficiency reaches 3.65 kWh/L, and the maximum thermal efficiency reaches 44.8%, leading among mass-produced range-extenders.

The distributed electric drive technology can significantly improve the drive experience with safety pleasure. SERES has always believed that “safety is the ultimate luxury”. SERES Power is actively developing the distributed e-drive systems, including dual-motor, three-motor, and four-motor distributed architecture, which can meet the power needs of vehicles from Class A to Class D.

It is reported that vehicles equipped with range-extended technology have become a top choice among high-end luxury consumers, offering convenient and efficient mobility without range or charging anxiety. As a pioneer and leader in range-extender technology, SERES has obtained over 3,900 patents and won over 100 honors.

SERES Super Range-Extender System has been widely applied and achieved success in China, helping AITO achieve strong sales. As of now, REEV AITO sales top 750,000 units. AITO 9 leads the ¥500,000-level luxury car segment.

SERES is currently cooperating with 25 industry partners. In 2024, SERES Power achieved an annual revenue of 9.2 billion yuan, with 132% year-on-year growth. The sales volume of its powertrains surpassed 600,000 units, and its motor and electronic control products exceeded 900,000 units.

SINGAPORE, Sept. 11, 2025 /PRNewswire/ — TVM Capital Healthcare, a global private equity investor and operator specialized in healthcare growth capital across emerging markets, today announced the first closing of its USD 150 million TVM Healthcare Southeast Asia Fund (“SEA Fund”).

The SEA Fund is the third generation of TVM Capital Healthcare funds and builds on the firm’s nearly 40 years of global healthcare investment and operator experience, including over 15 years of scaling healthcare companies across the Middle East and Southeast Asia. TVM Capital Healthcare has a strong track record of creating leading specialty care providers and advancing innovative care models outside of traditional hospital settings that expand access and improve quality of healthcare delivery.

Commitments to the SEA Fund have come from a broad group of leading institutional investors, including cornerstone investor, Invest International, founded by the Dutch government and FMO to support Dutch businesses and international partners with financing solutions that drive sustainable economic growth and create positive social and environmental impact worldwide.

The TVM Healthcare Southeast Asia Fund will focus on underpenetrated market segments where demand is high, but supply remains limited, including but not limited to post-acute and rehabilitation services, women’s health, diabetic and oncology care, and local manufacturing of essential pharmaceuticals. By addressing these urgent needs, the fund reinforces the resilience of healthcare as an investment sector and its fundamental importance to economic and social development.

In addition to scaling local specialty care clinics to become national and regional leaders, TVM Capital Healthcare also strategically invests in healthcare innovators from the US and Europe, directing their expansion into Southeast Asian target markets, as well as building cross-border partnerships such as those it has established with US-based, Harvard-affiliated teaching hospitals and leading European medtech companies —  to help accelerate the transfer of proven models of care, advanced medical technologies, and global best practices into local ecosystems.

The firm’s model emphasizes operational partnerships, global accreditations, and robust governance structures, enabling companies to grow as best-in-class businesses and supporting the leapfrogging of emerging market healthcare systems into new standards of care.

Hoda Abou-Jamra, Co-Founder and Managing Partner of Southeast Asia, TVM Capital Healthcare, said:
“This first close marks an important step in supporting Southeast Asia’s healthcare ecosystem and entrepreneurs. By combining capital with operational expertise and introducing proven healthcare models from around the world, we are helping to create companies that can lead nationally and regionally, improve access to quality care, and contribute to building sustainable healthcare systems.”

Jannie Tsuei, Partner, TVM Capital Healthcare, added:
“We see a unique opportunity in Southeast Asia’s healthcare sector, particularly in specialty care and medical manufacturing. With our investment strategy that combines local growth with international expansion, we can help companies scale into institutional-quality leaders delivering impactful healthcare outcomes.”

Eelco Benink, Head of Equity at Invest International, commented:
“Robust and equitable health care systems ensure that economies can become and remain resilient. Invest International is proud to anchor TVM Capital Healthcare’s SEA Fund. Its strategy — delivering accessible, quality healthcare while ensuring strong ESG performance — aligns with our mission to create sustainable impact by linking local companies to global solutions. Together, we will help build healthcare infrastructure that benefits patients and supports long-term development.”

About TVM Capital Healthcare

TVM Capital Healthcare is a global private equity investor and operator focused on specialty care and healthcare growth capital across emerging markets. With nearly 40 years of global investment and operational experience and 15 years in emerging markets, the firm builds and scales companies in Southeast Asia and the Middle East while also investing in healthcare innovators from the US and Europe and guiding their expansion into these markets. TVM Capital Healthcare’s portfolio companies advance access to care, improve patient outcomes, and align with national healthcare transformation agendas.

About Invest International

Invest International supports Dutch companies in the international financing of innovative solutions that contribute to the realization of the UN’s Sustainable Development Goals and the future earning capacity of BV Nederland. The financial focus is on five sectors in which the Netherlands excel: Water & Infrastructure, Energy, Healthcare, Sustainable Production and Agri-food. Invest International is a state-owned company, a joint venture of the Dutch Ministry of Finance (51 percent) and the development bank FMO (49 percent). The head office is located in The Hague.

Contact:
Holly Radel
Radel@tvmcapitalhealthcare.com

As an international network, Unreasonable Food is uniquely positioned to scale high-growth ventures dedicated to creating a more sustainable food system.

NEW YORK, Sept. 11, 2025 /PRNewswire/ — Today, as part of the Unreasonable Food^™ collaboration, Mars and Unreasonable Group are welcoming the next generation of growth stage ventures into the Unreasonable Food family.

Mars and Unreasonable Group welcome the next generation of growth into the Unreasonable Food family.

Evolving our food system will never be a simple journey, yet it remains one of the most practical levers we have for building a more resilient future and a thriving economy. Unreasonable Food, a bold collaboration between Mars Snacking and Unreasonable Group, was born in 2024 to back entrepreneurs turning our most pressing food chain challenges into unprecedented opportunities.

“Addressing the challenges in our food system is a task bigger than any one organization,” said Amanda Davies, Chief R&D, Procurement and Sustainability Officer for Mars Snacking. “That’s why it’s so important to build a collaborative ecosystem – connecting brilliant minds behind pioneering ventures with scaled industry leaders – so we can help unlock new possibilities and accelerate the transformation toward a more resilient future.”

Mars, in collaboration with Unreasonable Group, has selected fourteen purpose-led ventures that represent the next frontier of sustainability advancements. The 2025 Unreasonable Food cohort will build upon the work started in 2024, with a strategic focus on reducing dairy cattle emissions, scaling sustainable ingredients, and exploring solutions with partners around sustainable colors.

This critical work will continue to move us toward the next phase of developing a food system that is more sustainable and nutritious, for all.

Meet the 2025 Unreasonable Food Cohort:

• Alpine Bio: Engineering crops like soybeans to produce dairy proteins, enabling familiar melt, stretch, and creaminess without cows.
• Standing Ovation: Producing animal-free casein via precision fermentation to deliver authentic dairy textures for cheese and other foods.
• Oobli: Harnessing sweet proteins from plants to create sugar-like taste with no sugar, made scalable through fermentation.
• Debut Biotechnology: Fermenting high-value ingredients, including natural color alternatives, to replace unsustainable or synthetic sources.
• Octarine Bio: Producing a vibrant palette of natural colors through fermentation, offering reliable, sustainable options for food and textiles.
• DE3PBIO: Using AI and biotech to unlock plant-based functional ingredients that make foods cleaner, healthier, and more nutritious.
• NuCicer: Breeding new chickpea varieties with up to 75% more protein, improving taste, texture, and resilience to climate stress.
• Plantible Foods: Extracting Rubi protein from lemna (duckweed), a highly sustainable plant that can replace eggs, dairy, and additives.
• Hydrosome Labs: Leveraging ultrafine bubbles to boost fermentation yields and nutrient delivery, making biomanufacturing more efficient.
• Pow.bio: Pioneering continuous fermentation technology that reduces costs and increases capacity for bio-based production.

The 2024 inaugural cohort has continued to demonstrate what’s possible when high-growth companies are supported by an ecosystem connected by shared sustainability ambitions.  Since joining the program in 2024, our first cohort reported nearly an additional $200 million in revenue, 140,000 tons of CO₂e avoided, 310 million liters of water conserved, and 1.14 million kilograms of food sold. They reached 24 million more people with safe, nutritious food and educated 2 million more people on climate change mitigation and adaptation, while growing job opportunities improving working conditions across their communities.

“We’re honored to welcome these entrepreneurs to the Unreasonable Food family,” said Daniel Epstein, CEO of Unreasonable Group. “Their work reflects our shared ambition to evolve the food system in ways that are sustainable and inclusive. In collaboration with Mars, we stand ready to offer mentorship, convene stakeholders, and surface opportunities that can accelerate their journeys.”

The collective 2024 and 2025 class of ventures will engage with Mars teams across the enterprise, Unreasonable Food mentors, and a global investor network to further support their culture changing work, which will center around two shared priorities: transforming food supply chains and shaping the future of food.

For more information about Unreasonable Food and the Year 2 cohort, please visit Unreasonable Food.

About Mars, Incorporated

Mars, Incorporated is driven by the belief that the world we want tomorrow starts with how we do business today. As an approximately $55bn family-owned business, our diverse and expanding portfolio of leading pet care products and veterinary services support pets all around the world and our quality snacking and food products delight millions of people every day. We produce some of the world’s best-loved brands including ROYAL CANIN^®, PEDIGREE^®, WHISKAS^®, CESAR^®, DOVE^®, EXTRA^®, M&M’S^®, SNICKERS^® and BEN’S ORIGINAL^™. Our international networks of pet hospitals, including BANFIELD^™, BLUEPEARL^™, VCA^™ and ANICURA^™ span preventive, general, specialty, and emergency veterinary care, and our global veterinary diagnostics business ANTECH^® offers breakthrough capabilities in pet diagnostics. The Mars Five Principles — Quality, Responsibility, Mutuality, Efficiency and Freedom — inspire our 150,000 Associates to act every day to help create a better world for people, pets and the planet.

For more information about Mars, please visit www.mars.com. Join us on Facebook, Instagram, LinkedIn and YouTube.

About Unreasonable Group, LLC

Unreasonable is a Colorado-based, international company that supports a Fellowship for growth-stage entrepreneurs, channels exclusive deal-flow to investors, and partners with some of the world’s leading brands to ensure a more just future. The 501 ventures in the Unreasonable Fellowship operate across more than 180 countries, have collectively generated $20bn in revenue, raised $20bn in financing, and are positively impacting the lives of more than 1,434,646,829 people. As a global community, Unreasonable exists to re-purpose capitalism. Sound Unreasonable? We hope so. Because reasonable ideas seldom change anything.

For more information about Unreasonable, please visit www.unreasonablegroup.com

For Media Inquiries:

jolaade@unreasonablegroup.com

angelina.franco.pesci@effem.com

LAS VEGAS, Sept. 11, 2025 /PRNewswire/ — Sigenergy, a leading energy innovator, will showcase its comprehensive lineup of cutting-edge energy solutions at Intersolar South America, Booth W1.30. With an expanded and versatile product range designed for both residential and commercial & industrial (C&I) applications, the company aims to empower Latin America to strengthen grid resilience and accelerate the transition toward energy independence.

C&I Energy Solutions

Sigenergy will introduce its advanced C&I inverter portfolio to the Latin American market, covering PV, HYA, and HYB models with power ratings ranging from 50 kW up to 125 kW. Among them, the HYB model features seamless on/off-grid switching, with support for capacities of up to 110 kW. Up to three inverters can be paralleled without requiring an additional energy gateway, enabling a direct and highly reliable off-grid transition.

Complementing the inverter portfolio, the SigenStack energy storage system delivers a scalable, high-density DC-coupled solution. Each battery module provides 12 kWh, and a single inverter can connect up to 21 modules, reaching 250 kWh of storage capacity. With optimized Round-Trip Efficiency (+2%), modular scalability, and simplified deployment, SigenStack helps businesses reduce costs, maximize energy utilization, and boost resilience.

Sigenergy also provides a range of Energy Gateways in various configurations, enabling seamless on/off-grid transition across different application scenarios.

Residential Energy Solutions

At the heart of Sigenergy’s residential portfolio is the SigenStor, the world’s first 5-in-1 energy system. Already a global success, SigenStor has been embraced by installers and homeowners worldwide. It integrates a PV inverter, battery, EV charger, EMS, and PCS into one compact and modular unit. Each battery comes in 5/6/8/9 kWh options, with up to six units stacked to provide more than 54 kWh per system. By connecting multiple systems in parallel, SigenStor can also scale to meet the needs of C&I projects.

Sigenergy also presents its second-generation hybrid inverter, designed for residential use. With a fanless design and a slim profile of only 99 mm, it achieves industry-leading efficiency of up to 99% on three-phase models. In off-grid mode, it delivers up to 200% peak output, while operating at ultra-low noise levels (below 25 dB). Battery-ready for future upgrades, the inverter reduces total ownership costs while ensuring long-term flexibility. With an IP66 rating and wide operating range (-30°C to 60°C), it delivers robust performance in diverse environments.

To further expand applications in Rapid Shutdown scenarios and the growing balcony PV segment, Sigenergy introduces the SigenMicro microinverter. Incorporating patented DAB topology, the industry’s first built-in EMS, and IP67 protection, it redefines safety and reliability. Its WLAN Mesh architecture extends communication coverage by 1600%, with self-healing capability within 150 ms if a connection is lost. Designed for high efficiency and simple deployment, SigenMicro enables full commissioning in just five minutes.

Visit Sigenergy at Booth W1.30 to explore how its next-generation energy solutions are shaping a smarter, greener future for Latin America.